Hester Bios

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE782E01017
  • NSEID: HESTERBIO
  • BSEID: 524669
INR
2,049.30
-4.8 (-0.23%)
BSENSE

Jun 18

BSE+NSE Vol: 10.29 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Sakar Healthcare
Fredun Pharma
NGL Fine Chem
Hester Bios
Beta Drugs Ltd
Ind-Swift Labs.
Amrutanjan Healt
Jagsonpal Pharma
Windlas Biotech
Hikal
Indoco Remedies
Why is Hester Biosciences Ltd ?
1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.67 times
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.67 times
  • The company has been able to generate a Return on Capital Employed (avg) of 8.56% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Operating profit has grown by an annual rate 4.14% of over the last 5 years
3
With ROCE of 12.4, it has a Very Expensive valuation with a 3.3 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 5.75%, its profits have risen by 95.3% ; the PEG ratio of the company is 0.3
4
Despite the size of the company, domestic mutual funds hold only 0% of the company
  • Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Hester Bios should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Hester Bios for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Hester Bios
14.1%
0.16
36.97%
Sensex
-4.95%
-0.49
12.94%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
9.19%
EBIT Growth (5y)
4.14%
EBIT to Interest (avg)
5.08
Debt to EBITDA (avg)
3.94
Net Debt to Equity (avg)
0.52
Sales to Capital Employed (avg)
0.55
Tax Ratio
24.20%
Dividend Payout Ratio
21.66%
Pledged Shares
0
Institutional Holding
0.38%
ROCE (avg)
8.83%
ROE (avg)
10.95%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
32
Industry P/E
34
Price to Book Value
4.84
EV to EBIT
28.50
EV to EBITDA
22.30
EV to Capital Employed
3.52
EV to Sales
5.81
PEG Ratio
0.34
Dividend Yield
0.34%
ROCE (Latest)
12.36%
ROE (Latest)
14.91%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

23What is working for the Company
PAT(Q)

At Rs 14.04 cr has Grown at 988.4%

ROCE(HY)

Highest at 15.11%

DEBT-EQUITY RATIO(HY)

Lowest at 0.54 times

NET SALES(Q)

Highest at Rs 100.11 cr

PBDIT(Q)

Highest at Rs 34.33 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 34.29%

PBT LESS OI(Q)

Highest at Rs 25.18 cr.

-10What is not working for the Company
INTEREST(Q)

At Rs 5.10 cr has Grown at 180.22%

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 6.54 cr

Loading Valuation Snapshot...
Here's what is working for Hester Bios
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 25.18 cr has Grown at 135.33%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 14.04 cr has Grown at 988.4%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Debt-Equity Ratio - Half Yearly
Lowest at 0.54 times and Fallen
each half year in the last five half yearly periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Sales - Quarterly
Highest at Rs 100.11 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 100.11 cr has Grown at 22.19%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 34.33 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 34.29%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 25.18 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Here's what is not working for Hester Bios
Interest - Quarterly
At Rs 5.10 cr has Grown at 180.22%
Quarter on Quarter (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Cash and Cash Equivalents - Half Yearly
Lowest at Rs 6.54 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents